Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS

Wall Street analysts project Zimmer Biomet (ZBH) to report Q2 earnings of $1.98 per share, a 1.5% year-over-year decline, on revenues of $2.04 billion, a 5.3% increase. Notably, the consensus EPS estimate saw a 0.4% upward revision over the past 30 days, signaling analysts' re-evaluation. Segment-wise, Net Sales- S.E.T. are expected to surge 14.4% to $536.91 million, while Knees and Hips sales are projected to grow modestly by 2.8% and 3.2% respectively. Despite these varied forecasts, ZBH shares have underperformed the S&P 500 recently, and the stock carries a Zacks Rank #4 (Sell), suggesting potential future underperformance.

Analysis

Zimmer Biomet (ZBH) is approaching its Q2 earnings report with a mixed set of analyst expectations, signaling a potential divergence between top-line growth and bottom-line profitability. Wall Street projects a 5.3% year-over-year revenue increase to $2.04 billion, yet anticipates a 1.5% decline in earnings per share to $1.98. A critical detail is the 0.4% upward revision to the consensus EPS estimate over the past 30 days, suggesting a slight improvement in analyst sentiment leading into the announcement. A breakdown of revenue forecasts reveals that the S.E.T. (Surgical, Sports Medicine, Extremities and Trauma) segment is the primary growth driver, with an expected 14.4% YoY sales increase to $536.91 million. This robust performance contrasts sharply with the more modest growth anticipated in the larger Knees (+2.8%) and Hips (+3.2%) segments. Geographically, growth is forecast to be stronger in the U.S. (+6.2%) than internationally (+4.4%). Despite these pockets of strength, the stock has underperformed the S&P 500 over the last month and carries a Zacks Rank #4 (Sell), indicating a cautious outlook that likely weighs the expected margin contraction more heavily than the revenue growth.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings report for management's commentary on margin pressure, as this is the key factor driving the forecasted 1.5% EPS decline despite solid revenue growth.
• Pay close attention to the S.E.T. segment's performance, as its expected 14.4% growth is the primary driver of the company's top-line expansion and any deviation could significantly impact the stock's reaction.
• Given the Zacks #4 (Sell) rating and recent stock underperformance, a cautious stance is warranted; investors may consider waiting for a post-earnings catalyst before initiating or adding to positions.